A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial.

Summary, in English

The main objective was to study the effect on progression-free survival (PFS) of adding erlotinib to bevacizumab as maintenance treatment following chemotherapy and bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC).

• Author: Anders Johnsson; Helga Hagman; Jan-Erik Frödin; Åke Berglund; N. Keldsen; Eva Fernebro; J Sundberg; R De Pont Christensen; K-L Garm Spindler; D Bergström; A Jakobsen
• Department/s: BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation
• Publishing year: 2013
• Language: English
• Pages: 2335-2341
• Publication/Series: Annals of Oncology
• Volume: 24
• Issue: 9
• Links: http://www.ncbi.nlm.nih.gov/pubmed/23788755?dopt=Abstract; http://dx.doi.org/10.1093/annonc/mdt236
• Document type: Journal article
• Publisher: Oxford University Press
• Topic: Cancer and Oncology
• Status: Published
• ISBN/ISSN/Other: ISSN: 1569-8041